Results 171 to 180 of about 121,769 (336)

Glycogen synthase kinase 3 (GSK-3) controls T-cell motility and interactions with antigen presenting cells [PDF]

, 2020
Alison Taylor, Christopher E. Rudd
openalex   +1 more source

Nanomaterials‐mediated glycolysis rewriting to potentiate tumor immunotherapy

BMEMat, EarlyView.
This review systematically summarizes cutting‐edge advances in glycolysis‐rewiring nanomedicines, emphasizing their mechanisms in reversing immunosuppression and reinvigorating antitumor immune responses. Challenges in clinical translation and future directions for designing multifunctional metabolic‐immune modulators are also critically discussed ...
Zilin Ma, Songyan Li, Jie Yan, Xuechun Wang, Wen Zhao, Yunxuan Song, Dongdong Liu, Jianwei Jiao, Xiuying Duan, Guiqiang Zhang   +9 more
wiley   +1 more source

PB2203: INCIDENCE AND PREVALENCE OF MYELOFIBROSIS IN GERMANY: A RETROSPECTIVE CLAIMS DATA ANALYSIS

HemaSphere, 2023
Sophia Junker, Alexander Slowley, Joachim Göthert, Tim D’estrube, Kelesitse Phiri, Martin Krammer, Lena Sofie Weinmann, Florian Karl, Suzanne Landi, Sabrina Müller, Boris Gorsh   +10 more
doaj   +1 more source

GSK‐3 activity in neocortical cells is inhibited by lithium but not carbamazepine or valproic acid

, 2005
W. Jonathan Ryves, Emma Dalton, Adrian J. Harwood, Robin S. B. Williams   +3 more
openalex   +2 more sources

P2–082: A randomised, single–blind, placebo–controlled, multicentre study to investigate the pharmacodynamic effects of lithium on GSK–3 activity in patients with mild Alzheimer's disease [PDF]

, 2006
Peter Annas, Johannes Schröder, Lutz Frölich, Matthias W. Riepe, I.L. Kraft, Thomas Gasser, Thomas Lehye, Alexander Kurz, Hans Basun, Harald Hampel   +9 more
openalex   +1 more source

Nrf2 activation through the PI3K/GSK-3 axis protects neuronal cells from Aβ-mediated oxidative and metabolic damage [PDF]

, 2020
Krystal Sotolongo, Jorge Ghiso, Agueda Rostagno   +2 more
openalex   +1 more source

Population Pharmacokinetics and Exposure–Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis

Clinical Pharmacology &Therapeutics, EarlyView.
Momelotinib, a Janus kinase (JAK) 1/JAK2/activin A receptor type 1 inhibitor, is approved for the treatment of myelofibrosis with anemia. These analyses characterized the population pharmacokinetics of momelotinib and its active metabolite M21 following administration of the commercial tablet formulation in patients with myelofibrosis from phase II/III
Benjamin Rich, Meenakshi Srinivasan, Yu Liu Ho, Sandra A.G. Visser, Geraldine Ferron‐Brady, Georgios Vlasakakis   +5 more
wiley   +1 more source

P964: PATIENT (PT)-REPORTED OUTCOMES IN PTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH BELANTAMAB MAFODOTIN (BELAMAF) VS POMALIDOMIDE/LOW DOSE DEXAMETHASONE (PD) IN THE DREAMM-3 STUDY

HemaSphere, 2023
Vania Hungria, Katja Weisel, Brooke Currie, Sue Perera, Neal Sule, Wei He, Astrid Mckeown, Sandhya Sapra, Linda Nelsen, Mary LI, Sophie Barale, Julia Boyle, Kaytlyn Mcpoyle, Meletios A. Dimopoulos   +13 more
doaj   +1 more source

Improving Genotype Imputation in High‐Dimensional Pharmacogenomics Using Multiple Imputation: Evaluation with Machine Learning Approaches

Clinical Pharmacology &Therapeutics, EarlyView.
Multiple imputation is well‐established for handling missing data, yet its use in high‐dimensional genetic datasets remains limited. Using pharmacokinetic tuberculosis simulations and SNP data (1000 Genomes Project), we compared machine learning (ML) and traditional approaches (e.g., mean imputation and complete‐case analysis) for imputation and ...
Innocent G. Asiimwe, Tao You, Daniel F. Carr, Munir Pirmohamed, Geraint Davies, Andrea L. Jorgensen, on behalf of the UNITE4TB Consortium   +6 more
wiley   +1 more source

P24, a glycogen synthase kinase 3 (GSK 3) inhibitor

, 2002
Marı́a Isabel Martı́n, Jesús Vázquez, Jesús Ávila, Francisco J. Moreno   +3 more
openalex   +2 more sources